ReviewHematology/oncology clinics of North America2013
Management of patients with biochemical recurrence after local therapy for prostate cancer.
Review in Hematology/oncology clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.Nutrients · 2023Trial
- Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Trial
- A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.The Prostate · 2015Trial
- Trial
- Article
- Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis.European journal of nuclear medicine and molecular imaging · 2025Article
- Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.Journal of cancer research and clinical oncology · 2024Article
- Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?Therapeutic advances in medical oncology · 2024Review
- Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.Cold Spring Harbor molecular case studies · 2023Article
- Analytical Validation ofMethods and protocols · 2022Article
- The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.Cancers · 2022Review
- Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study.Computational and mathematical methods in medicine · 2022Article
- Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research.Cancers · 2020Review
- Immunotherapy for Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2019Review
- Pre-diagnostic carbohydrate intake and treatment failure after radical prostatectomy for early-stage prostate cancer.Cancer causes & control : CCC · 2019Article
- Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions.Frontiers in oncology · 2019Review
- Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention.International urology and nephrology · 2018Article
- Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.The Journal of urology · 2017Observational
- MiR-20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells.Cancer cell international · 2017Article
- Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.